On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system

Science

Volumn 352, Issue 6281, 2016, Pages 61-67

  Adamo, Andrea ^a   Beingessner, Rachel L ^b   Behnam, Mohsen ^a,c   Chen, Jie ^a   Jamison, Timothy F ^b   Jensen, Klavs F ^a   Monbaliu, Jean Christophe M ^a,d   Myerson, Allan S ^a   Revalor, Eve M ^a,e   Snead, David R ^b,f   Stelzer, Torsten ^a,g   Weeranoppanant, Nopphon ^a   Wong, Shin Yee ^a,h   Zhang, Ping ^b,i  

^a USA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Nuvera Fuel Cells Inc   (United States)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Georgia Pacific Corporation   (United States)

^g UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^h SINGAPORE INSTITUTE OF TECHNOLOGY   (Singapore)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; DIPHENHYDRAMINE; FLUOXETINE; LIDOCAINE; DRUG;

DRUG; EQUIPMENT; INDUSTRIAL PRODUCTION; PHARMACEUTICAL INDUSTRY; PROCESSING; SUPPLY CHAIN MANAGEMENT;

ARTICLE; CHEMICAL REACTION; CONTINUOUS FLOW SYNTHESIS; CONTROLLED STUDY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HEAT TRANSFER; PRIORITY JOURNAL; QUALITY CONTROL; SHELF LIFE; SURFACE PROPERTY; MEDICAL LITERATURE; MEDICINAL CHEMISTRY; PROCEDURES; STANDARDS; SYNTHESIS;

CHEMISTRY, PHARMACEUTICAL; DIAZEPAM; DIPHENHYDRAMINE; LIDOCAINE; PHARMACEUTICAL PREPARATIONS; PHARMACOPOEIAS AS TOPIC;

EID: 84963574932     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf1337     Document Type: Article

References (38)

1. C. Badman, B. L. Trout, J. Pharm. Sci. 104, 779-780 (2015).
2. I. R. Baxendale et al., J. Pharm. Sci. 104, 781-791 (2015).
3. S. Byrn et al., J. Pharm. Sci. 104, 792-802 (2015).
4. R. F. Service, Science 347, 1190-1193 (2015).
5. S. Mascia et al., Angew. Chem. Int. Ed. 52, 12359-12363 (2013).
6. Food and Drug Administration, Strategic Plan for Preventing and Mitigating Drug Shortages (October 2013; www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM372566.pdf).
7. L. Malet-Sanz, F. Susanne, J. Med. Chem. 55, 4062-4098 (2012).
8. D. Webb, T. F. Jamison, Chem. Sci. 1, 675-680 (2010).
9. R. L. Hartman, J. P. McMullen, K. F. Jensen, Angew. Chem. Int. Ed. 50, 7502-7519 (2011).
10. V. Hessel, Chem. Eng. Technol. 32, 1655-1681 (2009).
11. R. J. Ingham et al., Angew. Chem. Int. Ed. 54, 144-148 (2015).
12. B. Gutmann, D. Cantillo, C. O. Kappe, Angew. Chem. Int. Ed. 54, 6688-6728 (2015).
13. M. Baumann, I. R. Baxendale, Beilstein J. Org. Chem. 11, 1194-1219 (2015).
14. F. Lévesque, P. H. Seeberger, Angew. Chem. Int. Ed. 51, 1706-1709 (2012).
15. M. D. Hopkin, I. R. Baxendale, S. V. Ley, Org. Biomol. Chem. 11, 1822-1839 (2013).
16. C. A. Correia, K. Gilmore, D. T. McQuade, P. H. Seeberger, Angew. Chem. Int. Ed. 54, 4945-4948 (2015).
17. M. Viviano, T. N. Glasnov, B. Reichart, G. Tekautz, C. O. Kappe, Org. Process Res. Dev. 15, 858-870 (2011).
18. P. Zhang, M. G. Russell, T. F. Jamison, Org. Process Res. Dev. 18, 1567-1570 (2014).
19. D. Ghislieri, K. Gilmore, P. H. Seeberger, Angew. Chem. Int. Ed. 54, 678-682 (2015).
20. P. R. D. Murray et al., Org. Process Res. Dev. 17, 1192-1208 (2013).
21. P. L. Heider et al., Org. Process Res. Dev. 18, 402-409 (2014).
22. D. J. Am Ende, in Chemical Engineering in the Pharmaceutical Industry, D. J. am Ende, Ed. (Wiley, NJ, 2011), chap. 1.
23. A. Adamo, P. L. Heider, N. Weeranoppanant, K. F. Jensen, Ind. Eng. Chem. Res. 52, 10802-10808 (2013).
24. C. F. Carter et al., Org. Process Res. Dev. 14, 393-404 (2010).
25. G. Rieveschl, Dialkylaminoalkyl benzhydryl ethers and salts thereof, U.S. Patent 2,421,714A, 3 June 1947.
26. S. Y. Wong, J. Chen, L. E. Forte, A. S. Myerson, Org. Process Res. Dev. 17, 684-692 (2013).
27. USP (U.S. Pharmacopeia), Monograph 34, 2597 (2014).
28. T. J. Reilly, J. Chem. Educ. 76, 1557 (1999).
29. N. M. Loefgren, B. J. Lundqvist, Alkyl glycinanilides, U.S. Patent 2,441,498, 11 May 1948.
30. USP (U.S. Pharmacopeia), Monograph 37, 3552-3553 (2014).
31. T. Sugasawa, M. Adachi, T. Toyoda, K. Sasakura, J. Heterocycl. Chem. 16, 445-448 (1979).
32. USP (U.S. Pharmacopeia), Monograph 37, 2580-2581 (2014).
33. B. Ahmed-Omer, A. J. Sanderson, Org. Biomol. Chem. 9, 3854-3862 (2011).
34. R. L. Hartman, J. R. Naber, N. Zaborenko, S. L. Buchwald, K. F. Jensen, Org. Process Res. Dev. 14, 1347-1357 (2010).
35. USP (U.S. Pharmacopeia), Monograph 37, 3035-3036 (2014).
36. Food and Drug Administration, FDA Perspective on Continuous Manufacturing, (February 2013; www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM341197.pdf).
37. S. L. Lee et al., J. Pharm. Innov. 10, 191-199 (2015).
38. S. D. Schaber et al., Ind. Eng. Chem. Res. 50, 10083-10092 (2011).